Apogee Therapeutics, Inc.
$84.19
+3.0%Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -19.9).
Valuation inputs: P/E -19.9, earnings yield N/A, momentum +3.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -28.3%, ROIC -31.3%).
Profitability stack: net margin 0.0%, ROE -28.3%, ROIC -31.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +3.5%, momentum +3.0%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Apogee Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Apogee Therapeutics, Inc. Fair Value Envelope
No Revenue Data
APGE has not reported any revenue values in the available annual periods.
Apogee Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
APGE has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
APGE has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
APGE has not reported any net profit margin values in the available annual periods.
Apogee Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Apogee Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Apogee Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that APGE stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 109.73, with estimates ranging from a low of 81.00 to a high of 140.00.
The consensus 1-year price target stands at 109.73, with estimates ranging from a low of 81.00 to a high of 140.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Apogee Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $145.12M worth of APGE shares, with no buying activity reported.
3 Months
0
0.00
56.0K
4.57M
-4.6M
-$4.57M
3-6 Months
0
0.00
1.8M
135.82M
-135.8M
-$135.82M
6-9 Months
0
0.00
62.8K
4.47M
-4.5M
-$4.47M
9-12 Months
0
0.00
6.4K
245.50K
-245K
-$245K
Top Buyers
No buying activity
Top Sellers
Fairmount Funds Management Llc
Director
$133.53M
Henderson Michael Thomas
Director, Officer: Chief Executive Officer
$8.17M
Dambkowski Carl
Officer: Chief Medical Officer
$2.46M
Henderson Jane
Officer: Chief Financial Officer
$964K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $145.12M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
APGE has not reported any dividend yield values in the available annual periods.
apge Dividend History
Learning Layer
Related Guides
Build conviction on APGE by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.